Scalper1 News
Small drug developer Esperion Therapeutics (ESPR) seesawed on the stock market in heavy early trading Tuesday as analysts gave a mixed reception to the company’s update late Monday on its cholesterol-drug candidate. Esperion said Monday that in its end-of-phase-two meeting with the FDA on its candidate ETC-1002 last week, the agency said it would not require cardiovascular outcomes data — data on whether the drug prevents heart attacks — in the Scalper1 News
Scalper1 News